Discovery Laboratories (DSCO) Daily Short Sale Trading Volume Through 9-29-09

September 30, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report through Tuesday, September 29th, 2009 and come to the following statistical conclusions. The chart below shows aggregated daily short volume in Discovery Laboratories (NASDAQ: DSCO) for August through September 29, 2009. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

Date Short Volume Total Volume Percent

9/29/2009 2,054,839 27,944,158 7.35%

9/28/2009 468,742 5,412,600 8.66%

9/25/2009 403,031 3,600,500 11.19%

9/24/2009 573,899 7,359,100 7.80%

9/23/2009 418,877 4,541,000 9.22%

9/22/2009 289,281 3,565,400 8.11%

9/21/2009 480,174 4,005,900 11.99%

9/18/2009 932,762 5,019,100 18.58%

9/17/2009 869,522 9,643,800 9.02%

9/16/2009 734,414 10,475,100 7.01%

9/15/2009 1,092,010 14,805,900 7.38%

9/14/2009 5,057,898 51,280,900 9.86%

9/11/2009 6,937,992 51,294,500 13.53%

9/10/2009 49,727 3,953,600 1.26%

9/9/2009 71,115 669,100 10.63%

9/8/2009 106,870 736,900 14.50%

9/4/2009 137,694 610,800 22.54%

9/3/2009 274,003 1,115,800 24.56%

9/2/2009 166,751 1,089,200 15.31%

9/1/2009 340,730 1,710,000 19.93%

8/31/2009 171,542 1,385,724 12.38%

8/28/2009 171,976 1,253,600 13.72%

8/27/2009 334,858 1,324,500 25.28%

8/26/2009 274,797 1,702,600 16.14%

8/25/2009 111,311 763,000 14.59%

8/24/2009 380,679 3,004,100 12.67%

8/21/2009 344,654 1,805,600 19.09%

8/20/2009 171,500 908,500 18.88%

8/19/2009 88,961 789,700 11.27%

8/18/2009 128,979 969,500 13.30%

8/17/2009 413,547 1,667,900 24.79%

8/14/2009 405,842 2,308,100 17.58%

8/13/2009 524,011 3,667,400 14.29%

8/12/2009 214,347 1,959,100 10.94%

8/11/2009 189,873 1,248,500 15.21%

8/10/2009 259,760 1,704,500 15.24%

8/7/2009 240,164 1,744,700 13.77%

8/6/2009 174,508 1,806,700 9.66%

8/5/2009 279,860 2,612,300 10.71%

8/4/2009 593,394 4,545,900 13.05%

8/3/2009 403,853 3,239,300 12.47%

Total 27,338,747 249,244,582 10.97%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The companya�s proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net

N@N

Discovery Laboratories (DSCO) Daily Short Sale Trading Volume Through 9-29-09